Amaral-Silva Gleyson Kleber do, Sánchez-Romero Celeste, Wagner Vivian Petersen, Martins Manoela Domingues, Pontes Hélder Antônio Rebelo, Fregnani Eduardo Rodrigues, Soares Fernando Augusto, Almeida Oslei Paes de, Rocha André Caroli, Santos-Silva Alan Roger, Fonseca Felipe Paiva, Vargas Pablo Agustin
Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil.
Department of Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep;124(3):286-295. doi: 10.1016/j.oooo.2017.05.511. Epub 2017 Jun 7.
The aim of this study was to investigate hMutS proteins in developing human tooth, ameloblastomas, and ameloblastic carcinoma and to determine whether the expression of these proteins has any prognostic potential.
Ten cases of developing human tooth, 39 ameloblastomas, and 2 ameloblastic carcinomas were used to determine the distribution of the proteins during the process of carcinogenesis. Simultaneously, another sample of 73 ameloblastomas was arranged in tissue microarray, and their clinical, microscopic, and radiographic features; treatment outcome; presence of BRAF-V600E mutation; and follow-up data were assessed to determine the prognostic relevance of the expression of hMutS (hMSH2, hMSH3, hMSH6) and Ki-67. hMSH2 and hMSH6 were significantly downexpressed in ameloblastomas (P = .0059) compared with developing human tooth (P < .0001).
hMSH2, hMSH3 expression were significantly associated with BRAF-V600E mutation (P < .05). Simultaneous overexpression of hMutS was associated with recurrence (P = .035); however, these did not predict the disease-free survival of patients (P > .05).
hMutS proteins are downregulated in ameloblastoma; moreover, simultaneous overexpression of these proteins in ameloblastoma was associated with recurrence but did not predict disease-free survival.
本研究旨在调查人类发育中牙齿、成釉细胞瘤和成釉细胞癌中的hMutS蛋白，并确定这些蛋白的表达是否具有任何预后潜力。
使用10例人类发育中的牙齿、39例成釉细胞瘤和2例成釉细胞癌来确定致癌过程中这些蛋白的分布。同时，将另一个包含73例成釉细胞瘤的样本制成组织芯片，并评估其临床、显微镜和影像学特征；治疗结果；BRAF-V600E突变的存在情况；以及随访数据，以确定hMutS（hMSH2、hMSH3、hMSH6）和Ki-67表达的预后相关性。与人类发育中的牙齿相比，成釉细胞瘤中hMSH2和hMSH6显著下调（P = 0.0059）（P < 0.0001）。
hMSH2、hMSH3的表达与BRAF-V600E突变显著相关（P < 0.05）。hMutS的同时过表达与复发相关（P = 0.035）；然而，这些并不能预测患者的无病生存期（P > 0.05）。
成釉细胞瘤中hMutS蛋白下调；此外，成釉细胞瘤中这些蛋白的同时过表达与复发相关，但不能预测无病生存期。
